The Hemp and CBD Market Has Separated Into a Regulated Nutraceutical Segment and an Unregulated Consumer Product and the FDA Has Finally Decided

The Plant That Was Legalised in 2018 and Has Been in Regulatory Limbo Ever Since

The 2018 US Farm Bill's removal of hemp and hemp-derived products from the Controlled Substances Act's Schedule I classification created the commercial opportunity that the hemp and cannabidiol industry had been anticipating since the CBD molecule's anxiolytic, anti-inflammatory, and analgesic properties began generating consumer interest in the mid-2010s. The Farm Bill's legalisation of hemp production and hemp-derived CBD created the legal pathway for hemp farming in US states, the commercial production of CBD extract from hemp plants whose THC content falls below the 0.3 percent threshold that defines hemp rather than marijuana under federal law, and the retail distribution of CBD-containing products through health food stores, online retail, and pharmacy channels whose willingness to stock CBD products had previously been constrained by the legal uncertainty that the CSA's Schedule I classification created. What the Farm Bill did not resolve, and what has been the defining commercial constraint on the hemp and CBD market's development from the 2018 legalisation through to 2026, is the regulatory status of CBD as a food ingredient, dietary supplement ingredient, or drug under the authority of the Food and Drug Administration whose 2018 approval of Epidiolex, the pharmaceutical-grade CBD medication for treatment-resistant epilepsy whose drug approval status the FDA argued precluded CBD's classification as a dietary supplement or food additive under the Federal Food, Drug, and Cosmetic Act's prior market exclusivity provisions for drug-approved substances.

The global hemp and CBD market, valued at approximately $8.9 billion in 2026 across CBD consumer products, industrial hemp fibre and grain, and CBD pharmaceutical applications, and growing at over fourteen percent annually toward $19 billion by 2031, has been operating through this regulatory gap in which the FDA's repeated signals that it considers CBD a drug-category substance whose sale in food and supplements requires new legislation or rulemaking have been contradicted by the state-level legalisations of hemp-derived CBD products, the retail distribution of CBD products through mainstream channels, and the consumer spending on CBD products that has continued to grow despite the federal regulatory ambiguity. The FDA's 2023 announcement that it would not pursue a regulatory pathway for CBD under the existing dietary supplement framework, combined with its indication that new legislation was the appropriate mechanism for the CBD regulatory framework, created the commercial crisis that prompted Congress to include CBD-specific provisions in the 2023 Agricultural Improvement Act reauthorisation and has created the regulatory framework whose clarity is gradually making the hemp and CBD market legible to institutional investors and mainstream consumer goods companies whose regulatory risk appetite requires the framework certainty that the FDA has been providing through its 2025 and 2026 rulemaking activity.

Charlotte's Web and the Nutraceutical Brand Story

Charlotte's Web, the US CBD company named after Charlotte Figi, the child with Dravet syndrome whose treatment with hemp extract gained national attention in 2013 and whose story created the mainstream consumer awareness of CBD that preceded its federal legalisation, has built the most recognised consumer CBD brand in the United States through the combination of its brand heritage, its full-spectrum hemp extract product range, and its distribution through Whole Foods Market, CVS Health, and Vitamin Shoppe whose mainstream retail placement created the consumer accessibility that the early CBD market's natural food store concentration had not achieved. Its commercial trajectory since the 2018 Farm Bill legalisation has reflected the regulatory uncertainty's commercial impact most directly: the initial surge in CBD consumer spending that followed the Farm Bill created the revenue growth whose reversal from 2020 onward as the FDA's regulatory ambiguity created the mainstream retailer caution that removed CBD products from the pharmacy and grocery shelves of the major chains whose commercial scale could have delivered the revenue growth that Charlotte's Web's Farm Bill-era investor expectations had priced in. Lazarus Naturals, the Portland Oregon CBD company whose high-potency, low-price positioning and its Assistance Program that provides CBD products at reduced cost to veterans, low-income individuals, and those with disabilities creates the social mission differentiation that the commoditising CBD market's price competition has preserved as a commercial moat, represents the direct-to-consumer CBD brand whose quality certification and its third-party testing transparency have built the customer loyalty that the regulatory environment's consumer confidence challenge requires to sustain repeat purchase behaviour.

The industrial hemp market, whose fibre, hurd, and grain products create the commercial applications for hemp that are distinct from the CBD extract market and whose regulatory status is unambiguously legal under the Farm Bill's hemp production provisions, provides the commercial foundation that hemp farmers and processors whose CBD market exposure has been complicated by regulatory uncertainty have been developing as the diversification strategy that reduces their dependence on CBD price and regulatory outcomes. Hemp fibre's applications in biocomposite materials, insulation, textiles, and paper, hemp seed oil's nutritional supplement and food ingredient applications, and hemp grain's protein supplement market create the hemp market segments whose commercial trajectory is independent of the CBD regulatory resolution and whose growth is driven by the sustainability credentials that bio-based material substitution creates in the packaging, construction, and consumer goods markets whose ESG commitments are driving bio-based material specification.

The 2026 Regulatory Framework and Its Commercial Consequence

The FDA's 2025 proposed rulemaking for hemp-derived CBD products, which established the framework for CBD's classification as a dietary supplement ingredient with specific safety documentation requirements, maximum daily serving limits, and label claim restrictions, has created the regulatory clarity whose commercial consequence is the bifurcation of the hemp and CBD market into the regulated nutraceutical segment whose FDA framework compliance requires the safety substantiation, manufacturing quality, and labelling accuracy that the supplement industry's regulatory infrastructure provides, and the unregulated consumer product segment whose claims for CBD's health benefits are not supported by the FDA dietary supplement framework and whose continued distribution through informal retail channels creates the market quality differentiation that compliant CBD nutraceutical brands can exploit as the regulatory enforcement that the framework enables begins to remove non-compliant products from mainstream retail shelves.

Top 10 Companies in Hemp, CBD, and Industrial Hemp Markets Globally

1. Charlotte's Web: US CBD company with Whole Foods, CVS, and Vitamin Shoppe distribution and brand heritage from Charlotte Figi; its full-spectrum hemp extract and its mainstream retail distribution create the CBD brand whose consumer recognition and its retail placement define the commercial benchmark for the hemp-derived CBD nutraceutical segment's mainstream consumer positioning.
2. Lazarus Naturals: US high-potency CBD company with Assistance Program for veterans and low-income consumers; its price-value positioning and its third-party testing transparency create the CBD brand whose social mission differentiation and its quality certification build the consumer trust that the commoditising CBD market's price competition cannot replicate.
3. Medterra: US CBD wellness company with pharmaceutical-grade CBD isolate products and retail distribution; its USP-verified quality standard and its broad wellness product range create the CBD company whose pharmaceutical-grade quality credentials serve the consumer segment whose CBD purchase decision is most influenced by the quality assurance that pharmaceutical manufacturing standards provide.
4. HempFlax: Netherlands industrial hemp company with hemp fibre processing for biocomposites and construction; its European hemp fibre production and its automotive and construction material applications create the industrial hemp company whose fibre products serve the bio-based material substitution market that is growing independently of CBD regulatory outcomes.
5. Canopy Growth: Canadian cannabis company with US CBD market through hemp-derived CBD brands including BioSteel sports nutrition; its US CBD market presence and its Canadian cannabis heritage create the international cannabis company whose US hemp market strategy is built on the regulatory arbitrage between the Canadian cannabis framework and the US hemp-derived CBD market.
6. NextEvo Naturals: US water-soluble CBD company with enhanced bioavailability CBD formulation technology; its nano-emulsion CBD and its bioavailability differentiation create the CBD formulation company whose technology addresses the bioavailability limitation of oil-based CBD whose absorption efficiency in the gastrointestinal environment limits the active dose delivered from the stated milligram quantity.
7. Elixinol: Australian-US CBD company with international distribution across US, Europe, and Japan; its international regulatory navigation and its organic hemp sourcing create the CBD company whose geographic diversification across the multiple regulatory frameworks governing hemp-derived CBD serves the multinational consumer goods companies whose product development requires regulatory-approved CBD ingredient supply across multiple jurisdictions.
8. IND Hemp: US industrial hemp processing company with grain, fibre, and CBD co-production; its vertically integrated hemp processing and its co-product economics create the industrial hemp company whose production model maximises the per-acre economics of hemp cultivation by extracting commercial value from each component of the plant rather than focusing exclusively on the CBD extract whose price volatility creates the revenue risk that fibre and grain co-products partially offset.
9. Green Brands (cbdMD): US CBD brand with broad consumer product range and athlete ambassador programme; its sports and wellness positioning and its third-party testing create the CBD company whose athlete endorsement strategy targets the active consumer segment whose performance recovery application of CBD is the most commercially accessible entry point for consumers whose wellness supplement adoption history makes CBD a natural addition to their supplement routine.
10. Manitoba Harvest (Hempfoods): Canadian hemp food company with hemp seed, hemp protein, and hemp oil consumer products; its food-legal hemp product range and its mainstream retail distribution create the hemp company whose food products are commercially unaffected by the CBD regulatory ambiguity because the hemp seed and its derivatives have a separate and unambiguous food ingredient status that predates and is independent of the CBD regulatory question.